<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132235</url>
  </required_header>
  <id_info>
    <org_study_id>ENBRECAP2009</org_study_id>
    <nct_id>NCT01132235</nct_id>
  </id_info>
  <brief_title>An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use</brief_title>
  <acronym>ENBRECAP2009</acronym>
  <official_title>An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Academic Dermatology Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Academic Dermatology Centers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of re-treatment with etanercept 50mg&#xD;
      subcutaneous injections twice weekly for 12 weeks in subjects who have previously been&#xD;
      treated etanercept and efficacy diminished.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving a Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12 will measure efficacy of retreatment with etanercept</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>50mgs subcutaneous injections twice a week for 12 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with psoriasis who have previously been treated with etanercept for a minimum&#xD;
             of 6 months and discontinued treatment due to loss of efficacy. Every attempt will be&#xD;
             made to obtain loss of efficacy history from the subject's medical chart;when&#xD;
             etanercept was commenced and terminated and description of patient's psoriasis on&#xD;
             termination and details of new treatment commenced. Subjects must have failed their&#xD;
             latest psoriasis treatment after a period of three months. This will be measured as a&#xD;
             PGA of ≥ 3.&#xD;
&#xD;
          -  There is no specific requirement as to when prior treatment with etanercept occurred&#xD;
             and no requirement as to what type of treatment(s) used between initial and subsequent&#xD;
             treatments.&#xD;
&#xD;
          -  Are ≥ 18 years of age&#xD;
&#xD;
          -  PGA ≥ 3&#xD;
&#xD;
          -  BSA minimum of 5%&#xD;
&#xD;
        Tuberculosis inclusion criteria&#xD;
&#xD;
          -  Have no history of latent or active TB prior to screening.&#xD;
&#xD;
          -  Have no signs or symptoms suggestive of active TB upon medical history and/or physical&#xD;
             examination.&#xD;
&#xD;
          -  Have had no recent close contact with a person with active TB.&#xD;
&#xD;
          -  Within 1 month prior to the first administration of study have a negative tuberculin&#xD;
             skin test.&#xD;
&#xD;
               -  The ability to give written informed consent and comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current enrollment in any other investigational device or investigational drug&#xD;
             trial(s), or receipt of any other investigational agent(s) within 28 days before&#xD;
             baseline visit.&#xD;
&#xD;
          -  Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to&#xD;
             have antibodies to etanercept.&#xD;
&#xD;
          -  Latex sensitivity [NB: only applicable if they are using prefilled syringe or&#xD;
             prefilled SureClick™ autoinjector presentations]&#xD;
&#xD;
          -  Prior or concurrent use of cyclophosphamide therapy&#xD;
&#xD;
          -  Concurrent sulfasalazine therapy.&#xD;
&#xD;
          -  A positive HBV test or known history of any other immuno-suppressing disease.&#xD;
&#xD;
          -  Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family&#xD;
             member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis&#xD;
             medication.&#xD;
&#xD;
          -  Active or chronic infection within 4 weeks before screening visit, or between the&#xD;
             screening and baseline visits.&#xD;
&#xD;
          -  History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection and&#xD;
             Hepatitis C, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome,&#xD;
             chronic recurring infections or active TB, or other opportunistic infections&#xD;
&#xD;
          -  If etanercept was previously discontinued due to a serious adverse event&#xD;
&#xD;
          -  Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or&#xD;
             myocardial infarction, cerebrovascular accident or transient ischemic attack within 6&#xD;
             months of screening visit; unstable angina pectoris; uncontrolled hypertension&#xD;
             (sitting systolic BP &lt;80 mm Hg or &gt; 160 or diastolic BP &gt; 100 mm Hg); oxygen-dependent&#xD;
             severe pulmonary disease; history of cancer within 5 years [other than resected&#xD;
             cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer])&#xD;
&#xD;
          -  Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis,&#xD;
             optic neuritis or seizure disorder.&#xD;
&#xD;
          -  Use of a live vaccine 90 days prior to screening visit, or concurrent use of a live&#xD;
             vaccine.&#xD;
&#xD;
          -  Any condition or circumstances judged by the patient's physician [or the investigator&#xD;
             or medically qualified study staff] to render this clinical trial detrimental or&#xD;
             otherwise unsuitable for the patient's participation.&#xD;
&#xD;
          -  Female subjects who are pregnant, nursing or planning pregnancy (both men and women)&#xD;
             and not using acceptable methods of birth control during the trial (hormonal,&#xD;
             barriers, abstinence).&#xD;
&#xD;
          -  Women who are breast feeding&#xD;
&#xD;
        History of non-compliance with other therapies.&#xD;
&#xD;
          -  History of alcohol abuse within the last 12 months&#xD;
&#xD;
          -  Concurrent use of anakinra&#xD;
&#xD;
          -  Subjects who cannot discontinue any of the drugs below for 2 weeks prior to the&#xD;
             baseline visit or during the study;&#xD;
&#xD;
        A two week wash out period is appropriate as it would be unethical to expect subjects whose&#xD;
        disease if flaring to remain untreated for a longer period of time. The first dose of&#xD;
        etanercept will be administered two weeks after the last biologic dose.&#xD;
&#xD;
          -  Immunosuppressants, antimalarials, or sulfasalazine.&#xD;
&#xD;
          -  Other Ani-TNFs&#xD;
&#xD;
          -  Cyclosporine&#xD;
&#xD;
          -  Efalizumab&#xD;
&#xD;
          -  Azathioprine&#xD;
&#xD;
          -  Hydroxyurea&#xD;
&#xD;
          -  Live vaccines&#xD;
&#xD;
          -  Tacrolimus&#xD;
&#xD;
          -  Oral retinoids (isotretinoin,acitretin,bexarotene)&#xD;
&#xD;
          -  Ultra violet light therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Academic Dermatology Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika M Grant, RN.MBA</last_name>
      <phone>305-324-2110</phone>
      <phone_ext>210</phone_ext>
      <email>annikagrant@bellsouth.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Francisco A Kerdel, M.D.</name_title>
    <organization>Florida Academic Dermatology Centers</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

